

Effect of Folate Targeted Immunotherapy on the Survival of Mice with Lung Tumor Implants





Fig. 1

24JK-FBP Tumor Imaging

FIG. 2



Phase Contrast






Fluorescence

F1TC

Fig. 3

$C_2 + nea + ed$

$F_1^a + e - FITC$



↑
FITC images

↑
PE images

↓
Transmitted

Tumor Growth Curve*




FIG. 4

Effect of Cytokine Combinations on Folate-Targeted Immunotherapy*




Fig. 5

Immunotherapy Update*




FIG. 6

Synergistic Effect of FEFITC and IL-2 in Folate-Targeted Immunotherapy




Fig. 7

The Effect of Mouse NK Cell Depletion on Folate Targeted Immunotherapy*




Fig. 8

Development of Cellular Immunity against the Parental M109 Tumor Cells




Fig. 9

-○- FEFITC (1500 nmol/kg), IL-2 (250,000 IU/day), and IFN- α (25,000 U/day)

-▲-▼-◆- PBS control groups at respective tumor implantation time points

PEFITC-Targeted Immunotherapy:
the IL-2 dosing effect on i.p. M109 Tumor




Fig. 10

IFN- α Further Enhances IL-2-augmented
Immunotherapeutic Effect of FEFITC in Mice
with Pre-existing Anti-FITC Antibody




Fig. 11

Effect of Depletion of CD8⁺ T cells on Folate-Targeted Immunotherapy




Fig. 12

The Effect of a Third Cytokine, GM-CSF on
Folate-Targeted Immunotherapy




Fig. 13

FEFITC-Targeted Immunotherapy:
the IFN- α dosing effect on i.p. M109 Tumor




Fig. 14

Folate-Targeted Immunotherapy: the effect of
DNP as a hapten against i.p. M109 Tumor




Fig. 15

**Synergistic Effect of FEFITC and IFN- α
against Intrapерitoneal M109 Tumor**




Fig. 16

Folate-DNP Further Enhanced the Therapeutic Effect of
a High Dose Combination of IL-2 and IFN- α in Mice
with Pre-existing Anti-DNP Antibody




Fig. 17